drugset / Trial / NCT02731534

Efficacy Study of Intravenous Iron Preparation to Iron Deficiency Anemia

NCT02731534 ↗

Phase 3 Completed 238 enrolled Zeria Pharmaceutical
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to confirm the non-inferiority of Z-213 compared to Saccharated Ferric Oxide using the maximum change in Hb from baseline over 12 weeks in patients with Iron-deficiency Anemia (IDA)

Timeline

Start
2016-05
Primary completion
2017-03
Completion
2018-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator Saccharated Ferric Oxide Unknown — Intravenous
Subject Z-213 Unknown — Intravenous